[go: up one dir, main page]

MA63861A1 - PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS - Google Patents

PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS

Info

Publication number
MA63861A1
MA63861A1 MA63861A MA63861A MA63861A1 MA 63861 A1 MA63861 A1 MA 63861A1 MA 63861 A MA63861 A MA 63861A MA 63861 A MA63861 A MA 63861A MA 63861 A1 MA63861 A1 MA 63861A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
enveloped virus
compositions
virus
enveloped
Prior art date
Application number
MA63861A
Other languages
French (fr)
Inventor
Ekaterina Aleksandrovna LOMKOVA
Dmitry Valentinovich MOROZOV
Aleksandr Olegovich IAKOVLEV
Aleksandra Aleksandrovna SOZONOVA
Lina Igorevna FEDORENKO
Marina Konstantinovna DVORIANKINA
Original Assignee
Joint Stock Company "Biocad"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021120143A external-priority patent/RU2021120143A/en
Application filed by Joint Stock Company "Biocad" filed Critical Joint Stock Company "Biocad"
Publication of MA63861A1 publication Critical patent/MA63861A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne le domaine des produits pharmaceutiques, de la thérapie génique et de la médecine, spécifiquement des compositions pharmaceutiques d'un vecteur à base de virus recombinant non enveloppé, en particulier le virus adéno-associé recombinant (rAAV), lesquelles compositions peuvent être des compositions aqueuses ou lyophilisées et peuvent être utilisées pour le traitement et la prévention de diverses maladies.The present invention relates to the field of pharmaceuticals, gene therapy and medicine, specifically to pharmaceutical compositions of a non-enveloped recombinant virus-based vector, particularly recombinant adeno-associated virus (rAAV), which compositions may be aqueous or lyophilized compositions and may be used for the treatment and prevention of various diseases.

MA63861A 2021-07-08 2022-07-04 PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS MA63861A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021120143A RU2021120143A (en) 2021-07-08 PHARMACEUTICAL COMPOSITION OF NON-ENCOUNTERED VIRUS
PCT/RU2022/050212 WO2023282796A2 (en) 2021-07-08 2022-07-04 Pharmaceutical composition of non-enveloped virus

Publications (1)

Publication Number Publication Date
MA63861A1 true MA63861A1 (en) 2024-10-31

Family

ID=84800844

Family Applications (1)

Application Number Title Priority Date Filing Date
MA63861A MA63861A1 (en) 2021-07-08 2022-07-04 PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS

Country Status (11)

Country Link
EP (1) EP4367252A4 (en)
CN (1) CN117999353A (en)
AR (1) AR126417A1 (en)
CL (1) CL2024000062A1 (en)
CO (1) CO2024000073A2 (en)
CR (1) CR20240004A (en)
EC (1) ECSP24001599A (en)
MA (1) MA63861A1 (en)
MX (1) MX2024000472A (en)
WO (1) WO2023282796A2 (en)
ZA (1) ZA202400124B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024209563A1 (en) * 2023-01-19 2025-07-10 Uniqure Biopharma B.V Pharmaceutical formulations of gene delivery vehicles
TW202525313A (en) * 2023-09-06 2025-07-01 瑞士商迪納柯公司 Methods of treatment of hypertrophic cardiomyopathy with aav gene therapy vectors and therapeutic formulations
WO2025114524A1 (en) * 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations for viral drug products

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116280A2 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
WO2015040002A1 (en) * 2013-09-19 2015-03-26 Crucell Holland B.V. Improved adenovirus formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
EP4360652A3 (en) * 2016-11-04 2024-06-26 Takeda Pharmaceutical Company Limited Adeno-associated virus formulations
US20210355454A1 (en) * 2018-07-24 2021-11-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116280A2 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
WO2015040002A1 (en) * 2013-09-19 2015-03-26 Crucell Holland B.V. Improved adenovirus formulations

Also Published As

Publication number Publication date
EP4367252A2 (en) 2024-05-15
CN117999353A (en) 2024-05-07
AR126417A1 (en) 2023-10-11
ZA202400124B (en) 2024-11-27
WO2023282796A3 (en) 2023-02-16
CO2024000073A2 (en) 2024-04-29
EP4367252A4 (en) 2025-04-30
ECSP24001599A (en) 2024-02-29
WO2023282796A2 (en) 2023-01-12
MX2024000472A (en) 2024-02-12
CR20240004A (en) 2024-06-11
CL2024000062A1 (en) 2024-06-14

Similar Documents

Publication Publication Date Title
MA63861A1 (en) PHARMACEUTICAL COMPOSITION OF NON-ENVELOPED VIRUS
MA34120B1 (en) PHARMACEUTICAL COMPOSITION
MA30413B1 (en) NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS CONTAINING NIMESULIDE, THEIR PREPARATION AND USE
MA40814A1 (en) Pharmaceutical compositions for combination therapy
MA40768B1 (en) Mono or di-substituted indole derivatives as dengue virus replication inhibitors
MA52154B1 (en) Pharmaceutical composition for anemia
MA30779B1 (en) PEDIATRIC TABLETS OF CAPECITABINE
MA30539B1 (en) PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES INDUCED BY THE GPR38 RECEPTOR.
MA58049B1 (en) GEM-DOUBLE-SUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
EP4008718A4 (en) HETEROARYLAMIDOPYRIDINOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS AN ACTIVE PRINCIPLE FOR PREVENTING OR TREATING AN AUTOIMMUNE DISEASE
MA39421A (en) EZRINE DERIVATIVES AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS
MA47082B1 (en) Aromatic carboxylic acid amides as bradykinin b1 receptor antagonists
TNSN01076A1 (en) ASSOCIATIONS OF GROWTH HORMONE SECRETAGOGUES AND ANTIDEPRESSANTS, AND COMPOSITIONS CONTAINING THEM
MA58093B1 (en) NEW INSULIN ANALOGUES AND THEIR USES
FR2870126A1 (en) RECOMBINANT LENTIVIRAL VECTOR FOR EXPRESSION OF FLAVIVIRIDAE PROTEIN AND ITS APPLICATIONS AS VACCINE
EP3845516A4 (en) NEW HIF-1alfa INHIBITOR, METHOD FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN ANGIOGENESIS-ASSOCIATED EYE DISEASE, CONTAINING THE SAME AS AN ACTIVE INGREDIENT
EP3785718A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN INFECTIOUS FLAVIVIRUS DISEASE
EP4349341A4 (en) PHARMACEUTICAL PREPARATION FOR THE PREVENTION OR TREATMENT OF PULMONARY FIBROSIS
EP4098261A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
MA62939A1 (en) PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND ITS USE
MA58507A1 (en) Levilimab aqueous pharmaceutical composition
FR3096579B1 (en) composition for the protection and repair of the hematoencephalic barrier (BBB)
MA27474A1 (en) VACCINE
EP3795170C0 (en) PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE
CA3171453C (en) Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy